Utilizing RNA interference to enhance cancer drug discovery
- 1 July 2007
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 6 (7) , 556-568
- https://doi.org/10.1038/nrd2355
Abstract
With the development of RNA interference (RNAi) libraries, systematic and cost-effective genome-wide loss-of-function screens can now be carried out with the aim of assessing the role of specific genes in neoplastic phenotypes, and the rapid identification of novel drug targets. Here, we discuss the existing applications of RNAi in cancer drug discovery and highlight areas in this process that may benefit from this technology in the future.Keywords
This publication has 65 references indexed in Scilit:
- Why is cancer drug discovery so difficult?Nature Reviews Drug Discovery, 2006
- New approaches to molecular cancer therapeuticsNature Chemical Biology, 2006
- Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cellsCancer Biology & Therapy, 2006
- Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular targetProceedings of the National Academy of Sciences, 2006
- Inhibition of Viruses by RNA InterferenceVirus Genes, 2006
- On the origin and functions of RNA-mediated silencing: from protists to manCurrent Genetics, 2006
- Protein Kinase Cε Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer TherapyCancer Research, 2005
- Human Argonaute2 Mediates RNA Cleavage Targeted by miRNAs and siRNAsMolecular Cell, 2004
- A System for Stable Expression of Short Interfering RNAs in Mammalian CellsScience, 2002
- Introduction of a Chimeric Chalcone Synthase Gene into Petunia Results in Reversible Co-Suppression of Homologous Genes in trans.Plant Cell, 1990